Latest:
Everyone Loves e-Prescribing! Right?
Electronic prescribing is rapidly gaining support from a diverse array of healthcare organizations, government agencies, and technology corporations.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Daniel Indelicato MD
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Daniel J. Brat, MD, PhD
Latest:
Dr. Daniel Brat on Characterizing Diffuse Lower Grade Gliomas
Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.
Daniel J. DeAngelo, MD, PhD
Daniel DeAngelo, MD, PhD, is chief of the Division of Leukemia at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.
Latest:
Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL
Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.
Daniel J. George, MD
Daniel J. George, MD, is the Eleanor Easley Distinguished Professor, a professor of medicine, a professor in urology, and a professor in surgery at the Duke University School of Medicine and a member of the Duke Cancer Institute.
Latest:
Overcoming Barriers to Cabazitaxel and Optimizing Sequencing
Evidence-based approaches to cabazitaxel use in mCRPC, addressing treatment sequencing after prior therapies, real-world underutilization trends, patient counseling on benefits and risks, and FDA guidance on dosing strategies to optimize outcomes while managing toxicity.
Daniel O'Connell, MD
Latest:
Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer
Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, is a professor of medicine (medical oncology) and urology, as well as the chief of Genitourinary Oncology, at Yale School of Medicine and Smilow Cancer Hospital
Latest:
Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer